SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • March 11th, 2010 • Achillion Pharmaceuticals Inc • Pharmaceutical preparations • Connecticut
THIS SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), effective as of the 9th day of March 2010, is entered into by Achillion Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 300 George Street, New Haven, CT 06511-6624 (the “Company”), and Mary Kay Fenton, residing at 1381 Farmington Avenue, West Hartford, Connecticut 06107 (the “Employee”). This Agreement amends and restates the Amended and Restated Employment Agreement between the Company and the Employee dated September 10, 2003, as amended (the “Prior Agreement”).
AMENDED AND RESTATED DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT by and between ACHILLION PHARMACEUTICALS, INC. and GCA THERAPEUTICS, LTD. Dated March 5, 2010Development, Commercialization and License Agreement • March 11th, 2010 • Achillion Pharmaceuticals Inc • Pharmaceutical preparations • New Jersey
THIS AMENDED AND RESTATED DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT (“Agreement”) is executed March 5, 2010 and is made effective as of February 1, 2010 (“Effective Date”) by and between ACHILLION PHARMACEUTICALS, INC., a Delaware corporation (“Achillion”), with its principal place of business at 300 George Street, New Haven, Connecticut 06511, USA, and GCA THERAPEUTICS, LTD., a New Jersey corporation (“GCAT”), with its principal place of business at 14 Wall Street, 20th Floor, New York, NY 10005, USA. Achillion and GCAT are sometimes referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
